Treatment monitoring – assessing the effectiveness of cancer therapies through ctDNA and cells

1. Minimal residual monitoring of blood cancer

Blood cancer is a type of cancer with a fast and complicated progression. After treatment, if not closely monitored, the possibility of recurrence and unpredictable progression can lead to danger to the patient. That places a great need for minimal residual (MRD) monitoring after blood cancer treatment to predict the likelihood of recurrence.

Dario C. (2010) showed that the number of residual blood cancer cells is closely related to the possibility of cancer recurrence.

MRD > 1%: Poor treatment outcome, recurrence is certain
0.1% < MRD < 1%: Up to 75% chance of recurrence
MRD < 0.01%: Treatment is effective (1)

2. Monitoring the ctDNA of cancer cells and the immune system to evaluate the effectiveness of cancer treatment

CtDNA is DNA that is unique to cancer cells, which allows us to assess the therapeutic effect of therapy. The absence of ctDNA indicates the possibility of successful treatment and vice versa (2).

With a solution of 523 oncogenes of 9 common cancers, Illumina’s NGS-based ctDNA monitoring offers the potential for successful diagnosis and treatment or metastasis and transformation of related cancers.

The immune system is closely related to cancer treatment. The increase or decrease in the number of cancer cells shows how responsive the body is to cancer therapy (3).

Biomedic's solution

1. Monitor minimal residual blood cancer

Biomedic provides a comprehensive solution from equipment to chemicals.


  • First FDA-approved of 10-color dry gel
  • Ready to use, easy to operate, highly stable
  • Save time, simplify the process
  • Eliminate loss, save costs

Machine system:

  • Get the most advanced CE-IVD
  • APD machine technology enhances efficiency 3 times more than traditional technology
  • High sample analysis speed 30,000 cells/sec

2. Monitoring the ctDNA of cancer cells and the immune system to assess the effectiveness of cancer treatment

The solution to evaluate all immune cells on the basis of Flow Cytometer technology with the DxFLEX system and the DuraClone breakthrough dry gel antibody kit offers outstanding advantages.



DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.



Model: CytoFLEX
Manufacturer: Beckman Coulter Life Sciences/ USA

The CytoFLEX Flow Cytometer is the most innovative flow cytometer system of Beckman Coulter. With compact design and high efficiency in work, CytoFlex provides and easy to use system with the impressive performance you need. Our system allows the researchers just focus on the science with no worry about instrument. Its superior sensitivity and resolution throughout all configurations give it the edge over other cytometry systems four times its size.

– Up to 3 lasers Violet-Blue-Red (V-B-R) and fully activated with 13 colors

– Ability to measure 100 nm particles with violet laser

– Includes 13 band pass filters: 450/45, 525/40 (2), 585/42, 610/20 (2), 660/10 (2), 690/50, 712/25, 780/60 (3)

– For higher throughput applications an optional plate loader module is available

– Smart software in acquisition and analysis CytExpert